Biosimilar Naming Fight: Could Brand Names For All Resolve The Problem?
Executive Summary
Brand and generic drug companies continued their debate on distinguishable INNs for biosimilars during a Federal Trade Commission meeting Feb. 4.
You may also be interested in...
Ease Regulations For Affordable Biosimilars, Groups Urge
Present biosimilar guidelines pose regulatory barriers to the launch of affordable medicines and are guided by transnational companies, claim leading civil society groups. They are calling for a review of international regulations that can facilitate the launch of lower-priced biotherapeutics.
FTC Biosimilars Workshop: Second Time’s The Charm?
Having failed to significantly influence the design of the federal approval pathway, the Commission is hoping to have an impact on product naming and state substitution laws.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.